Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron

BACKGROUND: Safe and effective treatments are needed to prevent severe outcomes in individuals with coronavirus disease 2019 (COVID-19). We report results from STAMP, a phase 2/3, multicenter, double-blind, randomized, placebo-controlled trial of adintrevimab, an extended half-life monoclonal antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ison, Michael G, Popejoy, Myra, Evgeniev, Nikolay, Tzekova, Maria, Mahoney, Kathryn, Betancourt, Natalia, Li, Yong, Gupta, Deepali, Narayan, Kristin, Hershberger, Ellie, Connolly, Lynn E, Yalcin, Ilker, Das, Anita F, Genge, John, Smith, Michelle, Campanaro, Ed, Hawn, Pamela, Schmidt, Pete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284338/
https://www.ncbi.nlm.nih.gov/pubmed/37351456
http://dx.doi.org/10.1093/ofid/ofad279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284338/
https://www.ncbi.nlm.nih.gov/pubmed/37351456
http://dx.doi.org/10.1093/ofid/ofad279

Ejemplares similares